AI assistant
ABIVAX — Regulatory Filings 2017
Dec 21, 2017
1063_iss_2017-12-21_fd0802c0-319f-4e15-a708-e0bfafb2c3b3.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
ABIVAX to Participate in "Corporate Access" Event in San Francisco, January 8 – 10, 2018
PARIS, Dec. 21, 2017, 8:00 a.m. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.
To schedule a meeting with ABIVAX, investors can register on the online system managed by the Company's US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [email protected].
About ABIVAX (www.abivax.com)
ABIVAX is mobilizing the body's natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.
Follow us on Twitter @ABIVAX_
Contacts
| ABIVAX | Investors |
|---|---|
| Finance | LifeSci Advisors |
| Didier Blondel | Chris Maggos |
| [email protected] | [email protected] |
| +33 1 53 83 08 41 | +41 79 367 6254 |
| French Media | US Media |
| ALIZE RP | LifeSci Public Relations |
| Caroline Carmagnol/Aurore Gangloff | Matt Middleman, M.D. |
| [email protected] | [email protected] |
| +33 6 64 18 99 59 / +33 1 44 54 36 65 | +1 646 627 8384 |